Stocktoria

ABBOTT LABORATORIES ABT

NYSE · stock · Pharmaceutical Preparations · website · IPO 1937-03-01 · LEI

ABBOTT LABORATORIES (ABT) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.51% (safety: stretched). FY2025 revenue was $44.3B at a 14.7% net margin.

Chart by TradingView
69/100
Stocktoria Quality Score · grade B
5/9
Piotroski F — financial health
4.85
Altman Z″ — distress risk · safe
1.8%
Dividend yield 5y avg · stretched · Dividend payout 63.1%
-2.53
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 4 6 6 7 7 6 6 6 5 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$110.91 as of 2026-08-01 · -16.4% 1y
$85.60$133.9452-wk

Beneish M-score: -2.53 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$163.9B
P / E25.1×
Dividend yield 5y avg1.8%
Net margin 5y avg18.6%
Return on equity 5y avg18.7%
Beta0.58
Employees122,000

Analyst price target

$118.42 +6.8% vs last
consensus: buy · 24 analysts
target range $103.00 – $135.00 · median $118.50
4 strong buy · 16 buy · 7 hold
Recent analyst actions
DateFirmRating
2026-07-28UBSBuy (main)
2026-07-17CitigroupBuy (main)
2026-07-17Piper SandlerOverweight (reit)
2026-07-17JP MorganOverweight (main)
2026-07-17Wells FargoOverweight (main)
2026-07-17TD CowenBuy (reit)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$6.06
Forward P / E18.3×

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Smart money · insiders, last 12 months

Insiders net bought +$1.1M on the open market · 2 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 63%
Net marginstronger than 87%
Return on equitystronger than 79%
Revenue growthstronger than 52%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 5/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.11
Retained earnings / assets0.574
EBIT / assets0.093
Equity / liabilities1.555

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ABTABBOTT LABORATORIES5/94.8525.1+5.7%
BMYBRISTOL MYERS SQUIBB CO7/916.7-0.2%
ABBVAbbVie Inc.7/9-0.34105.9+8.6%
PFEPFIZER INC4/917.8-1.6%
MRKMerck & Co., Inc.4/917.4+1.3%
LLYELI LILLY & Co7/955.1+44.7%
UPCUniverse Pharmaceuticals INC4/97.37-22.4%

All Manufacturing companies →

About ABBOTT LABORATORIES

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

FAQ

Is ABT financially healthy?

ABBOTT LABORATORIES's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does ABT pay a dividend, and is it safe?

Yes. ABBOTT LABORATORIES pays a dividend yielding about 2.51% with a 63.1% payout ratio, rated “stretched” for safety.

How profitable is ABT?

In FY2025, ABBOTT LABORATORIES had a net margin of 14.7% and a return on equity of 12.4%.

Is ABT overvalued or undervalued?

ABBOTT LABORATORIES trades at about 29.8× trailing earnings — below its 10-year norm (10-year range 16.7×–230.2×, median 42.3×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for ABT?

The average Wall-Street price target for ABBOTT LABORATORIES is $118.42, about 6.8% above the recent price, from 24 analysts (consensus: buy).

Is ABT a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on ABBOTT LABORATORIES: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 25.1×, a dividend yield of 2.51%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.